Pro Medicus Limited (ASX:PME)

Market Cap	18.17B -40.2%
Revenue (ttm)	261.69M +22.9%
Net Income	265.34M +130.3%
EPS	2.54 +130.3%
Shares Out	104.47M
PE Ratio	68.59
Forward PE	95.29
Dividend	0.74 (0.43%)
Ex-Dividend Date	Sep 7, 2026

Volume	223,339
Open	173.50
Previous Close	172.70
Day's Range	173.02 - 177.77
52-Week Range	107.75 - 321.57
Beta	0.58
Analysts	Buy
Price Target	202.47 (+16.4%)
Earnings Date	Aug 18, 2026

About Pro Medicus

Pro Medicus Limited, a healthcare informatics company, provides medical imaging software and services to hospitals, imaging centers, and health care groups in Australia, Europe, and North America. The company offers Visage RIS, an enterprise-class radiology information system for patient registration, billing, scheduling, typing, HL7 integration, financial reporting, picture archive and communication system (PACS) integration, digital dictation, and voice recognition integration; and Visage RIS/PACS, a solution for imaging needs of organization...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1983
• Employees: 153
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PME

Financial Performance

In fiscal year 2026, Pro Medicus's revenue was 261.69 million, an increase of 22.87% compared to the previous year's 212.98 million. Earnings were 265.34 million, an increase of 130.30%.

Analyst Summary

According to 15 analysts, the average rating for PME stock is "Buy." The 12-month stock price target is $202.47, which is an increase of 16.40% from the latest price.

Price Target

$202.47

(16.40% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error